Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06681337 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Universal CAR-T Cell Therapy for Refractory Lupus Nephritis

StatusUnknown
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 8, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
Trial Details
NCT Number NCT06681337
Lead Sponsor Bioray Laboratories
Collaborators: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions
(from sponsor)		 Lupus Nephritis
Related terms Lupus Nephritis
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov